Search results for "Ventricular hypertrophy"

showing 10 items of 107 documents

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Surve…

2018

Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF,…

MalePROGNOSISHypertension Left Ventricular Hypertrophy Atrial FibrillationRHYTHM-CONTROL THERAPYBlood PressureComorbidity030204 cardiovascular system & hematologyLeft ventricular hypertrophy0302 clinical medicineHeart RateRisk FactorsAtrial FibrillationRegistries030212 general & internal medicineStrokeRISKmedicine.diagnostic_testIncidencePULSE PRESSUREWOMENAtrial fibrillationMiddle AgedPulse pressureEuropeSurvival RateEchocardiographyPopulation SurveillanceHypertensionDisease ProgressionCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicineSTROKEmedicine.medical_specialtyCANADIAN REGISTRY03 medical and health sciencesAge DistributionInternal medicinemedicineHumansCOHORTcardiovascular diseasesSex DistributionRisk factorRetrospective Studiesbusiness.industryOdds ratiomedicine.diseaseComorbidityATHEROSCLEROSISElectrocardiography AmbulatorybusinessFOLLOW-UPElectrocardiographyFollow-Up Studies
researchProduct

Association of central and peripheral pulse pressure with intermediate cardiovascular phenoytpes

2012

Objective: We assessed the relationship between pulse pressure and intermediate cardiovascular phenotypes in a middle-aged cohort with high prevalence of hypertension. Background: It has been suggested that central pulse pressure (cPP) is a better predictor of cardiovascular outcome than peripheral pulse pressure (pPP), particularly in the elderly. Yet, it is unclear if cPP provides additional prognostic information to pPP in younger individuals. Methods: In 535 individuals we assessed cPP and pPP as well as the intermediate cardiovascular phenotypes pulse wave velocity (PWV; SphygmoCor, Complior, PulsePen), carotid intima-media thickness (C-IMT; carotid ultrasound), left-ventricular mass i…

MalePhysiologyintermediate cardiovascular phenotypesBlood Pressure030204 cardiovascular system & hematologysurrogate markersCohort Studiespressure0302 clinical medicineHeart Ratepulse wave analysis030212 general & internal medicinerisk-factorsstage renal-diseasePulse wave velocitypulse wave analysiMiddle AgedPhenotypePeripheralPulse pressureleft ventricular hypertrophyarterial stiffnessPhenotypeaortic pressureAortic pressureCardiologyall-cause mortalityFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyMean arterial pressurehypertensioncollaborative trial acctpulse wave velocityhypertension; intermediate cardiovascular phenotypes; intimamedia thickness; left ventricular hypertrophy; pressure; pulse wave analysis; pulse wave velocity; Adult; Cohort Studies; Female; Humans; Hypertension; Male; Middle Aged; Phenotype; Blood Pressure; Heart Rate; Internal Medicine; Physiology; Cardiology and Cardiovascular Medicinebrachial blood-pressurewave reflectionsteady component03 medical and health sciencesintermediate cardiovascular phenotypeInternal medicineHeart ratemedicineInternal MedicineHumansintima-media thicknessintimamedia thicknebusiness.industrymedicine.diseaseintimamedia thicknessBlood pressureIntima-media thicknessArterial stiffnessCohort Studiebusiness
researchProduct

2013 ESH/ESC Guidelines for the management of arterial hypertension

2013

Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ in many respects from the previous ones. Some of the most important differences are listed below: 1. Epidemiological data on hypertension and BP control in Europe. 2. Strengthening of the prognostic value of home blood pressure monitoring (HBPM) and of its role for diagnosis and management of hypertension, next to ambulatory blood pressure monitoring (ABPM). 3. Update of the prognostic significance of night-time BP, white-coat hypertension and masked hypertension. 4. Re-emphasis on integration of BP, cardiovascular (CV) risk factors, asymptomatic organ damage (OD) and clinica…

Maleblood pressure measurementPhysiologyEnfermedad cardiovascularWhite coat hypertensionLeft ventricular hypertrophyEpidemiologyfollow-upguidelinesblood pressureGeneral MedicineMiddle AgedEuropeOrgan damageRenal sympathetic denervationCardiologyFemaleCardiology and Cardiovascular MedicineRisk assessmentAdultcardiovascular risklifestylemedicine.medical_specialtyhypertensionAmbulatory blood pressureorgan damagecardiovascular complicationsCardiologíaPrehypertensionantihypertensive treatmentYoung AdultDevice therapyInternal medicineHipertensiónInternal MedicinemedicineHumansdevice therapyLife StyleAntihypertensive AgentsSistema cardiovascularAgedTask forcebusiness.industryta3121medicine.diseaseMasked HypertensionBlood pressureIntima-media thicknessbusinessJournal of Hypertension
researchProduct

Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension.

1999

We investigated the influence of major cardiovascular risk factors (smoking, hypercholesterolemia, diabetes mellitus) on the association between angiotensin-converting enzyme (ACE) gene insertion (I)/deletion (D) polymorphism and echocardiographic left ventricular mass in 225 patients with sustained hypertension, assessed by ambulatory blood pressure monitoring. When the study population was analyzed as a whole, the 3 ACE genotypes did not differ in left ventricular mass (II, 47 g/m2.7; ID, 49 g/m2.7; DD, 51 g/m2.7; p = NS). No difference was found in subjects (n = 135) in whom at least 1 major cardiovascular risk factor was present (II, 51 g/m2.7; ID, 51 g/m2.7; DD: 52 g/m2.7; p = NS). In …

Malemedicine.medical_specialtyAmbulatory blood pressureGenotypeHeart VentriclesPeptidyl-Dipeptidase ALeft ventricular hypertrophyPolymerase Chain ReactionMuscle hypertrophyRisk FactorsInternal medicineDiabetes mellitusmedicineHumansRisk factorAllelesRetrospective StudiesPolymorphism Geneticbiologybusiness.industryAngiotensin-converting enzymeOdds ratioDNABlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseasePrognosisEchocardiography DopplerCardiovascular DiseasesHypertensionCardiologybiology.proteinPopulation studyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessGene DeletionFollow-Up Studies
researchProduct

Relationship between transforming growth factor beta1 and progression of hypertensive renal disease.

2002

In this study the role of circulating transforming growth factor beta1 (TGFbeta1) on progression of renal hypertensive disease has been investigated. Fifty consecutive outpatients with essential hypertension were enrolled and divided into three groups, according to their urinary albumin excretion (UAE). Group A comprised 10 hypertensives with UAEor=20 mg/24 h (normoalbuminuric group); Group B included 21 hypertensives with UAE20300 mg/24 h (microalbuminuric group); Group C encompassed 19 hypertensives with UAEor= 300 mg/24 h (proteinuric group). In all patients UAE by immunonephelometric assay, circulating TGFbeta1 by a solid phase specific sandwich ELISA technique, BUN and creatinine by ro…

Malemedicine.medical_specialtyDiastoleLeft ventricular hypertrophyEssential hypertensionStatistics NonparametricMuscle hypertrophyExcretionTransforming Growth Factor beta1chemistry.chemical_compoundTransforming Growth Factor betaInternal medicineInternal MedicinemedicinePrevalenceAlbuminuriaHumansInterventricular septumCreatinineEjection fractionbusiness.industryMiddle Agedmedicine.diseasemedicine.anatomical_structureEndocrinologyHypertension RenovascularchemistryEchocardiographyCardiologyDisease ProgressionRegression AnalysisFemaleHypertrophy Left VentricularbusinessBiomarkersJournal of human hypertension
researchProduct

Interplay of cardiac remodelling and myocardial stiffness in hypertensive heart disease: a shear wave imaging study using high-frame rate echocardiog…

2019

Abstract Aims To determine myocardial stiffness by means of measuring the velocity of naturally occurring myocardial shear waves (SWs) at mitral valve closure (MVC) and investigate their changes with myocardial remodelling in patients with hypertensive heart disease. Methods and results Thirty-three treated arterial hypertension (HT) patients with hypertrophic left ventricular (LV) remodelling (59 ± 14 years, 55% male) and 26 aged matched healthy controls (55±15 years, 77% male) were included. HT patients were further divided into a concentric remodelling (HT1) group (13 patients) and a concentric hypertrophy (HT2) group (20 patients). LV parasternal long-axis views were acquired with an ex…

Malemedicine.medical_specialtyHeart DiseasesConcentric hypertrophy030204 cardiovascular system & hematologyConcentricLeft ventricular hypertrophy030218 nuclear medicine & medical imaging03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineInternal medicineMitral valvemedicineHumansRadiology Nuclear Medicine and imagingInterventricular septumVentricular remodelingAgedVentricular Remodelingbusiness.industryGeneral Medicinemedicine.diseaseHypertensive heart diseasemedicine.anatomical_structureParasternal lineEchocardiographyHypertensionCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessEuropean heart journal. Cardiovascular Imaging
researchProduct

Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease.

2009

To evaluate the prevalence of left ventricular hypertrophy (LVH) and left ventricular geometry in a group of 293 hypertensive patients with stage 2-5 chronic kidney disease (CKD), compared with 289 essential hypertensive patients with normal renal function.All patients underwent echocardiographic examination. Patients on stage 1 CKD, dialysis treatment, or with cardiovascular diseases were excluded.LVH was observed in 47.1% of patients with CKD and in 31.14% of essential hypertensive patients (P0.0001). We found increasingly higher left ventricular diameters, thicknesses, and mass from stage 2 to 5 CKD. Distribution of concentric and eccentric LVH was not different between the two groups. H…

Malemedicine.medical_specialtyHeart diseasePhysiologyRenal functionGuidelines as TopicLeft ventricular hypertrophyMuscle hypertrophyElectrolytesCatecholaminesInternal medicineReninInternal MedicinemedicineDiabetes MellitusPrevalenceHumansLeft ventricular geometrycardiovascular diseasesStage (cooking)AldosteroneAgedbusiness.industryCase-control studyBlood Pressure DeterminationMiddle Agedmedicine.diseaseEchocardiography DopplerItalyCase-Control StudiesCreatinineChronic DiseaseHypertensionCardiologyRegression AnalysisFemaleHypertrophy Left VentricularKidney DiseasesNefropatie croniche ipertrofia ventricolare sinistra ipertensione arteriosaCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration RateJournal of hypertension
researchProduct

Impact of type 2 diabetes on left ventricular geometry and diastolic function in hypertensive patients with chronic kidney disease.

2010

Left ventricular hypertrophy (LVH) and diastolic dysfunction are very common in patients with chronic kidney disease (CKD). Aim of this study was to evaluate the impact of type 2 diabetes on LV geometry and diastolic function in hypertensive patients with CKD. We enrolled 288 Caucasian subjects with hypertension and CKD; of them, 112 had diabetes. Patients with cardiovascular (CV) diseases, glomerular filtration rate (GFR)60 ml min(-1) per 1.73 m(2), dialysis treatment and other major non-CV diseases were excluded. All patients underwent routine biochemical analyses and echocardiographic examination with tissue Doppler imaging (TDI). Patients with diabetes had significantly higher LV wall t…

Malemedicine.medical_specialtyHeart diseasemedicine.medical_treatmentRenal functionType 2 diabetesComorbidityLeft ventricular hypertrophyInternal medicineDiabetes mellitusInternal MedicinemedicinePrevalenceHumansRenal Insufficiency ChronicDialysisAgedUltrasonographyheart diseasesVentricular Remodelingbusiness.industryMiddle Agedmedicine.diseaseleft ventricular hypertrophySurgeryBlood pressureDiabetes Mellitus Type 2diabeteHypertensionCardiologydiastolic dysfunctionFemaleHypertrophy Left Ventricularbusinesschronic kidney diseaseKidney diseaseGlomerular Filtration RateJournal of human hypertension
researchProduct

Left ventricular diastolic function and cardiometabolic factors in obese normotensive children

2014

Abstract Background and aim Left ventricular (LV) hypertrophy and diastolic function have been found to be associated with obesity and hypertension in adults. However, there are scarce data about the association of obesity itself to cardiac alteration in children. The aim of this study was to detect early changes in LV structure and function in obese children and whether they are associated with the biomarkers of metabolic risk and endothelial activation. Methods and results A total of 130 children aged 7–16 years (88 obese and 42 normal-weight children) were studied. All children had normal resting blood pressure. Two-dimensional ultrasound with M-mode imaging was performed to assess the L…

Malemedicine.medical_specialtyMean arterial pressureAdolescentHeart VentriclesEndocrinology Diabetes and MetabolismDiastoleVascular Cell Adhesion Molecule-1Medicine (miscellaneous)Left ventricular hypertrophyBody Mass IndexMuscle hypertrophyEndothelial activationVentricular Dysfunction LeftRisk FactorsInternal medicinemedicineHumansMass indexObesityProspective StudiesChildUltrasonographyMetabolic SyndromeNutrition and DieteticsApolipoprotein A-Ibusiness.industrymedicine.diseaseCross-Sectional StudiesEarly DiagnosisBlood pressureSolubilityCardiovascular DiseasesSpainCardiologyFemaleCardiology and Cardiovascular MedicinebusinessRetinol-Binding Proteins PlasmaBody mass indexBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Comparison of N-terminal proB-type natriuretic peptide levels at different stages of visceral leishmaniosis and in patients with chronic kidney disea…

2018

N-terminal proB-type natriuretic peptide (NT-proBNP) may be a useful marker in canine leishmaniosis (CanL). The aim was to compare NT-proBNP in dogs at different LeishVet stages of CanL and with idiopathic chronic kidney disease (CKD). Dogs diagnosed with CanL or CKD and a group of healthy dogs were included (group A, five normal dogs; group B, six dogs LeishVet 1-2; group C, 13 dogs LeishVet 3-4; group D, six dogs with CKD). NT-proBNP was higher (P0.001) in group C (7.616 pmol/l, interquartile range (IQR) 3537-10,000 pmol/l) than in group A (293 pmol/l, IQR 257-373), group B (388.5 pmol/l, IQR 324-793) and group D (740 pmol/l, IQR 557-962 pmol/l). International Renal Interest Society (IRIS…

Malemedicine.medical_specialtyMyocarditisN-Terminal ProB-type Natriuretic Peptide040301 veterinary sciencesmedicine.drug_classLeft ventricular hypertrophyGastroenterologyGroup A0403 veterinary scienceDogsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideAnimalsHumansIn patientcardiovascular diseasesDog DiseasesRenal Insufficiency ChronicGeneral Veterinarybusiness.industry0402 animal and dairy science04 agricultural and veterinary sciencesGeneral Medicinemedicine.disease040201 dairy & animal sciencePeptide FragmentsLeishmaniasis VisceralFemalebusinesshormones hormone substitutes and hormone antagonistsBiomarkersKidney diseaseThe Veterinary record
researchProduct